[ Tips ] 一分鐘使用導覽
商品編號： 9-603-043 出版日期： 2003/04/15 作者姓名： Sucher, Sandra J.;McManus, Stacy 商品類別： Operations management 商品規格： 23p 再版日期： 2004/10/07 地域： Europe 產業： Biotechnology industry;Pharmaceutical industry 個案年度： 1999 - 1999
商品敘述：
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the unexpected data processed by Alex Matter, head of oncology research at Novartis, AG. CML was a rare form of cancer that affected a very small number of individuals in the world. The development of STI571 was a pioneering concept in genetically targeted drug development. This case enables students to decide whether and how they would advance the development, production, and distribution of the drug given these extraordinarily successful Phase 1 results. Provides details on factors that complicate this decision, including production complexity, precedents from other high-profile drug treatments, and market pressures.
涵蓋領域：
Innovation;Cross-functional management;Business law and ethics;Strategy formulation
相關資料：
哪些人也有訂購？